Efficacy and safety of Creon® 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis

Journal of Cystic Fibrosis

Volumn 8, Issue 6, 2009, Pages 370-377

  Trapnell, Bruce C ^a   Maguiness, Karen ^b   Graff, Gavin R ^c   Boyd, David ^d   Beckmann, Katrin ^e   Caras, Steven ^d  

^a UNIVERSITY OF CINCINNATI   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d Solvay Pharmaceuticals Inc   (Netherlands)

^e Solvay Pharmaceuticals GmbH   (Germany)

Author keywords

Coefficient of fat absorption; Coefficient of nitrogen absorption; Pancreatic enzyme replacement therapy; Pancreatin; Pancrelipase; Randomised, controlled trial

Indexed keywords

KREON; LIPID; NITROGEN; PLACEBO;

ABDOMINAL PAIN; ABNORMAL FECES; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FAT INTAKE; FECES ANALYSIS; FEMALE; FLATULENCE; HEADACHE; HUMAN; LIPID ABSORPTION; MALE; OUTCOME ASSESSMENT; PANCREAS EXOCRINE INSUFFICIENCY; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; EXOCRINE PANCREATIC INSUFFICIENCY; FATS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL ABSORPTION; MALE; PANCRELIPASE; PLACEBOS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70450221680     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.08.008     Document Type: Article

References (23)

1. Walkowiak J., Sands D., Nowakowska A., Piotrowski R., Zybert K., Herzig K.H., et al. Early decline of pancreatic function in cystic fibrosis patients with class 1 or 2 CFTR mutations. J Pediatr Gastroenterol Nutr 40 (2005) 199-201
2. Ferrone M., Raimondo M., and Scolapio J.S. Pancreatic enzyme pharmacotherapy. Pharmacotherapy 27 (2007) 910-920
3. Baker S.S., Borowitz D., and Baker R.D. Pancreatic exocrine function in patients with cystic fibrosis. Curr Gastroenterol Rep 7 (2005) 227-233
4. Wilschanski M. Nutrition in cystic fibrosis. In: Koletzko B. (Ed). Pediatric Nutrition in Practice (2008), Karger, Basel, Switzerland 224-228
5. Safdi M., Bekal P.K., Martin S., Saeed Z.A., Burton F., and Toskes P.P. The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. Pancreas 33 (2006) 156-162
6. Sander-Struckmeier S., Boyd D., and Caras S. Pancrelipase delayed-release capsules (CREON®): efficacy and safety in children less than 7 years old with pancreatic exocrine insufficiency due to cystic fibrosis. Presented at: 21st Annual Meeting of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (November 13-15, 2008) San Diego, CA
7. Stern R.C., Eisenberg J.D., Wagener J.S., Ahrens R., Rock M., doPico G., et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 95 (2000) 1932-1938
8. FitzSimmons S.C., Burkhart G.A., Borowitz D., Grand R.J., Hammerstrom T., Durie P.R., et al. High-dose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. New Engl J Med 336 (1997) 1283-1289
9. U.S. Food and Drug Administration. Questions and answers on exocrine pancreatic insufficiency drug products. http://www.fda.gov/CDER/DRUG/infopage/pancreatic_drugs/pancreatic_QA.htm . Published April 27, 2004. Accessed March 9, 2009.
10. U.S. Food and Drug Administration. FDA requires pancreatic extract manufacturers to submit marketing applications. FDA News. http://www.fda.gov/bbs/topics/news/2004/NEW01058.html. Published April 27, 2004. Accessed 8 August 2008.
11. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Exocrine Pancreatic Insufficiency Drug Products - Submitting NDAs. http://www.fda.gov/cder/guidance/6275fnl.htm. Published April 13, 2006. Accessed March 9 2009.
12. Trapnell B.C., Maguiness K., and Graff G.R. Efficacy and safety of a new formulation of CREON® in patients with exocrine pancreatic insufficiency due to CF. J Cystic Fibrosis 8 (2009) S80
13. Borowitz D., Baker R.D., and Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 35 (2002) 246-259
14. Sinaasappel M., Stern M., Littlewood J., Wolfe S., Steinkamp G., Heijerman H.G., et al. Nutrition in patients with cystic fibrosis: a European Consensus. J Cyst Fibros 1 (2002) 51-75
15. Stallings V.A., Stark L.J., Robinson K.A., Feranchak A.P., and Quinton H. Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 108 (2008) 832-839
16. Borowitz D., Durie P.R., Clarke L.L., Werlin S.L., Taylor C.J., Semler J., et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr Gastroenterol Nutr 41 (2005) 273-285
17. Kjeldahl J.T. A new method for the determination of nitrogen in organic matter. Z Anal Chem 22 (1883) 366-382
18. Allison D.B., and Casey D.E. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 62 Suppl 7 (2001) 22-31
19. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
20. Borowitz D., Konstan M.W., O'Rourke M.S., Cohen M., Hendeles L., and Murray F.T. Coefficients of fat and nitrogen absorption in healthy subjects and individuals with cystic fibrosis. J Pediatr Pharmacol Ther 12 (2007) 47-52
21. Heubi J.E., Boas S.R., Blake K., Nasr S.Z., Woo M.S., Graff G.R., et al. 246 EUR-1008 (a new pancreatic enzyme product, PEP) was shown to be safe and effective in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI). J Cystic Fibrosis 6 (2007) S61
22. Borowitz D., Goss C.H., Limauro S., Konstan M.W., Blake K., Casey S., et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 149 (2006) 658-662
23. Kuhn R.J., Eyting S., Henniges F., and Potthoff A. In vitro comparison of physical parameters, enzyme activity, acid resistance, and pH dissolution characteristics of enteric-coated pancreatic enzyme preparations: implications for clinical variability and pharmacy substitution. J Pediatr Pharmacol Ther 12 (2007) 115-128